Product Name :
ZCL278 — Cdc42 GTPase Inhibitor
Description:
ZCL278 is a potent and selective inhibitor of Cdc42 GTPase. ZCL278 directly binds to the binding site of the Cdc42 guanine nucleotide exchange factor intersectin (ITSN) and inhibits its functions (Kd ~6-11 µM). In Swiss 3T3 fibroblast cultures, ZCL278 abolished microspike formation and disrupted GM130-docked Golgi structures, two of the most prominent Cdc42-mediated subcellular events. ZCL278 reduces the perinuclear accumulation of active Cdc42 in contrast to NSC23766, a selective Rac inhibitor. ZCL278 suppresses Cdc42-mediated neuronal branching and growth cone dynamics as well as actin-based motility and migration in a metastatic prostate cancer cell line (i.e., PC-3) without disrupting cell viability. ZCL278 could be a powerful chemical tool for research of Cdc42 subclass of Rho GTPases in human pathogenesis, such as those of cancer and neurological disorders.
CAS:
587841-73-4
Molecular Weight:
584.89
Formula:
C21H19BrClN5O4S2
Chemical Name:
2-(4-bromo-2-chlorophenoxy)-N-((4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenyl)carbamothioyl)acetamide
Smiles :
CC1C=C(C)N=C(NS(=O)(=O)C2C=CC(=CC=2)NC(=S)NC(=O)COC2=CC=C(Br)C=C2Cl)N=1
InChiKey:
XKZDWYDHEBCGCG-UHFFFAOYSA-N
InChi :
InChI=1S/C21H19BrClN5O4S2/c1-12-9-13(2)25-20(24-12)28-34(30,31)16-6-4-15(5-7-16)26-21(33)27-19(29)11-32-18-8-3-14(22)10-17(18)23/h3-10H,11H2,1-2H3,(H,24,25,28)(H2,26,27,29,33)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
ZCL278 is a potent and selective inhibitor of Cdc42 GTPase. ZCL278 directly binds to the binding site of the Cdc42 guanine nucleotide exchange factor intersectin (ITSN) and inhibits its functions (Kd ~6-11 µM). In Swiss 3T3 fibroblast cultures, ZCL278 abolished microspike formation and disrupted GM130-docked Golgi structures, two of the most prominent Cdc42-mediated subcellular events. ZCL278 reduces the perinuclear accumulation of active Cdc42 in contrast to NSC23766, a selective Rac inhibitor. ZCL278 suppresses Cdc42-mediated neuronal branching and growth cone dynamics as well as actin-based motility and migration in a metastatic prostate cancer cell line (i.e., PC-3) without disrupting cell viability.{{Natamycin} web|{Natamycin} Bacterial|{Natamycin} Purity & Documentation|{Natamycin} References|{Natamycin} manufacturer|{Natamycin} Cancer} ZCL278 could be a powerful chemical tool for research of Cdc42 subclass of Rho GTPases in human pathogenesis, such as those of cancer and neurological disorders.{{Brigatinib} web|{Brigatinib} Anaplastic lymphoma kinase (ALK)|{Brigatinib} Protocol|{Brigatinib} References|{Brigatinib} supplier|{Brigatinib} Autophagy} |Product information|CAS Number: 587841-73-4|Molecular Weight: 584.PMID:34816786 89|Formula: C21H19BrClN5O4S2|Chemical Name: 2-(4-bromo-2-chlorophenoxy)-N-((4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenyl)carbamothioyl)acetamide|Smiles: CC1C=C(C)N=C(NS(=O)(=O)C2C=CC(=CC=2)NC(=S)NC(=O)COC2=CC=C(Br)C=C2Cl)N=1|InChiKey: XKZDWYDHEBCGCG-UHFFFAOYSA-N|InChi: InChI=1S/C21H19BrClN5O4S2/c1-12-9-13(2)25-20(24-12)28-34(30,31)16-6-4-15(5-7-16)26-21(33)27-19(29)11-32-18-8-3-14(22)10-17(18)23/h3-10H,11H2,1-2H3,(H,24,25,28)(H2,26,27,29,33)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO up to 100 mM|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|ZCL278 was used at 50 µM final concentration in various in vitro assays.|References:|Friesland A, et al. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. (2013) Proc Natl Acad Sci USA. 110(4):1261-6.Products are for research use only. Not for human use.|Documents||